QFIDYN
LIVE

Serial Number

97152382

Owner

CSL BEHRING GMBH

Attorney

Scott D. Woldow

Filing Date

Dec 2, 2021

Add to watchlist:

No watchlists yet
View on USPTO

QFIDYN Trademark

Serial Number: 97152382 • Registration: 7307766

QFIDYN is a trademark filed by CSL BEHRING GMBH on December 2, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

CSL BEHRING GMBH (101 trademarks)

EMIL-VON-BEHRING STRASSE 76
MARBURG (LAHN) , DE

Entity Type: 16

Trademark Details

Filing Date

December 2, 2021

Registration Date

February 20, 2024

Published for Opposition

December 5, 2023

Goods & Services

Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Feb 20, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Feb 20, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 5, 2023 NPUB
PUBLISHED FOR OPPOSITION
Dec 5, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 15, 2023 NONP
ELECTRONIC RECORD REVIEW COMPLETE
Oct 31, 2023 FIXD
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Oct 27, 2023 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 24, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 7, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 7, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 7, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 6, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jun 6, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jun 6, 2023 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
May 11, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 11, 2023 CRFA
ASSIGNED TO LIE
May 11, 2023 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 8, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 25, 2022 GNRN
NON-FINAL ACTION E-MAILED
Sep 25, 2022 GNRT
NON-FINAL ACTION WRITTEN
Sep 25, 2022 CNRT
ASSIGNED TO EXAMINER
Sep 12, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 6, 2021 NWOS
NEW APPLICATION ENTERED
Dec 6, 2021 NWAP